a n a ly s i s Association studies have greatly refined the understanding of how variation within the human leukocyte antigen (HLA) genes influences risk of multiple sclerosis. However, the extent to which major effects are modulated by interactions is poorly characterized. We analyzed high-density SNP data on 17,465 cases and 30,385 controls from 11 cohorts of European ancestry, in combination with imputation of classical HLA alleles,
Since the earliest reports of association between multiple sclerosis and genetic variation in the HLA genes 1 , linkage screens 2,3 and association studies [4] [5] [6] [7] [8] [9] [10] [11] , together with imputation of classical HLA alleles from linked SNP data 9, [12] [13] [14] , have established the key factors driving patterns of association. In populations of northern European origin, risk is dominated by the HLA-DRB1*15:01 allele, with additional effects from class II risk alleles (HLA-DRB1*03:01 (refs. 15, 16) and HLA-DRB1*13:03 (refs. 4,9) ) and class I protective alleles, including HLA-A*02:01 (ref. 9) , HLA-B*44:02 (ref. 7) and HLA-B*38:01 (ref. 14) . In addition, deviation from an additive model has been reported for some variants, with evidence that HLA-DRB1*15:01 exerts a dominant effect and HLA-DRB1*03:01 exerts a recessive effect 17 . However, the extent to which the effects of classical HLA alleles are modulated by interactions with alleles from other loci within or outside the HLA region remains to be established. Several studies have suggested the presence of such interactions [17] [18] [19] [20] [21] , although these did not achieve genome-wide significance or take account of linkage disequilibrium (LD) between alleles, population stratification and departures from additivity, any of which could either obscure or create false signals suggesting biological interaction. Furthermore, mouse models have indicated the presence of functional interactions between class II alleles 22 , although whether equivalent epistasis also occurs in humans is unknown. Interactions between classical HLA alleles and non-HLA risk-associated loci have been described previously for coding variation in the antigen-processing ERAP1 gene and the class I HLA-B*27 allele in ankylosing spondylitis 23 , HLA-C*06 in psoriasis 24 and HLA-B*51 in Behçet's disease 25 , findings that provide insights into the putative mechanisms of these diseases. However, thus far, no such interactions have been reported for multiple sclerosis.
RESULTS
To assess the evidence for interactions involving classical HLA alleles influencing genetic risk for multiple sclerosis and quantifiable features of the disease, we analyzed patterns of HLA association in 17,465 multiple sclerosis cases and 30,385 controls from across 11 independent cohorts genotyped as part of the Immunochip study (Supplementary Table 1 ). Classical HLA alleles were imputed at HLA-A, HLA-B, Class II HLA interactions modulate genetic risk for multiple sclerosis 1 1 0 8 VOLUME 47 | NUMBER 10 | OCTOBER 2015 Nature GeNetics a n a ly s i s HLA-C, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 and HLA-DPB1 from linked SNP data using previously published methods 12, 13, 26 . Using cross-validation, we estimate the accuracy at four-digit resolution to be between 0.95 and 0.99 across loci for a posterior probability threshold of 0.7 and call rates of between 0.90 and 1.00 across loci (Supplementary Table 2) , except for HLA-DPB1, for which limited training data were available, leading to a low call rate of 0.85 although the accuracy was 0.98. Uncertainty in HLA imputation, which is well calibrated 13 , was accounted for in our model analysis (Online Methods and Supplementary  Fig. 1 ). Validation accuracy for all alleles reported here is shown in Supplementary Table 3 . Population stratification within each cohort was controlled for by including the first five principal components of ancestry as covariates.
Our analysis had four goals: (i) to define the key components of genetic risk for multiple sclerosis arising from classical HLA alleles; (ii) to test for interactions among classical HLA alleles; (iii) to test for interactions between classical HLA alleles and non-HLA loci associated with multiple sclerosis; and (iv) to estimate the contribution of polygenic epistasis as a modulator of risk conferred by classical HLA alleles. We first used three stepwise approaches to construct a general logistic model of HLA risk for multiple sclerosis (Online Methods): analysis of the UK data set, guided initially by prior knowledge, followed by validation of known and new effects through fixed-effect meta-analysis across cohorts; an automated model search involving mega-analysis of all alleles at four-digit resolution; and an augmented automated model search involving additional groupings of alleles at serological (two-digit) resolution and sharing of amino acid residues at variable positions, similar to an approach used in earlier work 14 .
Our goal was to identify strong and repeatable signals of association most likely driven by classical HLA alleles and all other effects within the HLA region of comparable importance that cannot easily be attributed to classical HLA alleles. Only alleles with a fixed-effect meta-analysis P value of <1 × 10 −9 are reported, a conservative threshold chosen to identify factors with compelling evidence for association (approximately equivalent to P = 0.001 after correcting for genome-wide multiple testing). Deviations from additivity were considered in both the manually guided and automated approaches. The results from the three approaches identified a consistent set of factors, although there was some variation in the ranking and identity of the focal variants in cases where the LD between alleles was strong ( Supplementary Fig. 2) . A consensus approach was used to summarize the findings.
A high-resolution map of HLA risk for multiple sclerosis Across multiple cohorts of European ancestry, we found that the architecture of genetic risk for multiple sclerosis was dominated by a series of class II risk alleles (consistent with most risk signals being driven by alleles at HLA-DRB1) and a series of protective signals driven by class I alleles ( Fig. 1 and Table 1 ). Risk was dominated by the wellcharacterized HLA-DRB1*15:01 allele (odds ratio (OR) = 3.92; fixedeffect meta-analysis under a model including all reported effects, P = 2 × 10 −686 ), which was partially dominant (homozygous OR = 8.30, P = 8.5 × 10 −22 for the homozygote correction term, a measure of the deviation from additivity of the homozygous odds ratio). We also found largely recessive risk for HLA-DRB1*03:01 (heterozygous OR = 1.16, P = 3.5 × 10 −8 ; homozygous OR = 3.47, P = 1.3 × 10 −30 ), additive risk effects from HLA-DRB1*13:03 (OR = 2.62, P = 6.2 × 10 −55 ) and Figure 1 Overview of genetic effects in the HLA region influencing risk for multiple sclerosis. The relative locations of the classical HLA loci are shown (central bar) along with forest plots for each of the major effects identified. Each forest plot shows the estimated odds ratio from the cohort-specific logistic model and the 95% confidence interval, with point size proportional to sample size and the cohorts ordered by size (supplementary Table 1 (OR = 0.63, P = 6.9 × 10 −11 ), which, except for HLA-B*55:01, have been reported previously as being associated 7, 9, 14, 17 , although HLA-B*38:01 was not reported at genome-wide significance. We found departure, albeit weak, from additivity at HLA-A*02:01 (homozygous OR = 0.56, homozygous correction P = 3.3 × 10 −5 ; the protective effect was weakly dominant), which is important to include for analyses of interactions.
For several alleles, there were a number of SNPs and classical alleles at other loci in strong LD ( Table 1) , and these cannot be excluded as potential determinants of the signal. In addition, we found evidence for risk variants in the vicinity of HLA-DPB1 that correlated with HLA-DPB1*03:01 (OR = 1.33, P = 5 × 10 −36 ) but, as previously reported 9, 14, 27 , were strongest at rs9277565 (OR = 1.32, P = 2.1 × 10 −52 ; r 2 = 0.50). We also identified a missense variant in LTA, the gene encoding lymphotoxin α (rs2229092: C-allele OR = 1.33, P = 1.7 × 10 −22 ), which is in LD (r 2 ~0.50) with multiple other SNP variants in the samples of European ancestry from the 1000 Genomes Project and weak association (r 2 = 0.29) with the previously reported haplotype in MICB-LST1 (ref. 14) .
After accounting for these effects, no other classical HLA allele was associated in the UK (P < 1 × 10 −5 ), replicated in the meta-analysis (P < 1 × 10 −9 ) and identified by the automated model searches. The analysis of alleles grouped by serological activity or sharing of encoded amino acid residues led to similar conclusions as the analysis based on four-digit alleles; however, it identified a protective effect for HLA-B alleles that shared a cysteine residue at position 326 (OR = 0.84, P = 1.2 × 10 −24 ), and these alleles somewhat reduced the inferred protective effect of HLA-B*44:02 (although the latter remained genome-wide significant in a fixed-effect meta-analysis that included both). The grouping approach identified one shared amino acid residue (a serine at position 57 in HLA-DRβ1) that captured the risk associated with HLA-DRB1*08:01 and HLA-DRB1*13:03, although a model with separate effects for the two loci is preferred. The grouping approach also identified a homozygous protective effect for HLA-DQB1 alleles encoding a glycine residue at position 70, although this signal was better explained by an interaction.
Interactions among classical HLA alleles
Having defined the major loci affecting multiple sclerosis risk and their marginal mode of action, we next investigated evidence for interactions between the classical HLA alleles identified above and all other classical HLA alleles, within the UK cohort ( Fig. 2a and Supplementary Fig. 3 ). We found evidence for a strong protective effect of HLA-DQA1*01:01 only in the presence of HLA-DRB1*15:01 ( Fig. 2a) , which replicated in meta-analysis (OR = 0.65, P = 1.3 × 10 −17 ; Fig. 1 ). The strongest signal was seen at HLA-DQA1*01:01; however, this allele was in LD with HLA-DRB1*01:01 (r 2 = 0.6 in the UK), which also showed strong association (OR = 0.66, P = 5 × 10 −12 ). The interaction can also be explained as occurring between HLA-DRB1*15:01 and the presence of two copies of HLA-DQB1 alleles encoding a glycine residue at position 70 (OR = 0.60, P = 8 × 10 −33 ), with the evidence for the involvement of HLA-DQA1*01:01 being stronger in the UK but weaker in the combined analysis (Supplementary Table 4 ). npg a n a ly s i s A second allelic interaction involving HLA-DQB1*03:02 and HLA-DQB1*03:01 was also identified (Figs. 1 and 2a) , such that the latter abolished the risk associated with the former (OR in the presence of HLA-DQB1*03:02 = 0.60, P = 7.1 × 10 −12 ). No other pairs of alleles showed strong evidence for interaction within the UK cohort (P < 1 × 10 −5 ) and/or replicated in meta-analysis.
Interactions with non-HLA risk loci
We then tested for association between classical HLA alleles and 98 independent and previously identified non-HLA variants that influence risk for multiple sclerosis 11 . We found no evidence for interactions outside the HLA region involving any of the identified classical HLA alleles ( Fig. 2b and Supplementary Fig. 4) . Similarly, we found no evidence for interactions between classical HLA alleles and the effects of all non-HLA variants combined in a single risk score ( Fig. 2c and Supplementary Fig. 5 ). We note that, initially, no departure from additivity was included for HLA-A*02:01, which led to inflation of the interaction terms with non-HLA associated alleles. This inflation disappeared when the partially dominant effect of HLA-A*02:01 was included in the model, illustrating how failing to include departures from additivity can generate false evidence of interaction (Supplementary Fig. 6 ). Similar patterns were observed if the non-additive term for HLA-DRB1*15:01 was not included (Supplementary Fig. 6 ).
Testing for polygenic epistasis
Despite the lack of evidence for specific interactions, it is nevertheless possible that the effects of individual classical alleles are modulated by many weak effects at many loci across the genome. Such polygenic epistasis could be manifest by an elevated contribution of background relatedness to variation in disease risk in individuals who carry a specific risk allele. In theory, it would be possible to estimate separate random-effects components for additive and interacting components of background risk. However, in practice, such components are highly correlated, which makes efficient estimation for very large kinship matrices impractical. However, an alternative approach is to estimate the difference between cases and controls in the effect of background relatedness on predicting the allele of interest (Supplementary Note).
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Observed -log 10 (P value) Figure 3 Estimates of polygenic epistasis influencing the effects of major HLA loci on multiple sclerosis. Point estimates (X's) and 95% confidence intervals (lines; floored to zero) are shown for the ratio of the standard deviation in effect induced by genome-wide polygenic epistasis to the absolute magnitude of the average effect size for classical HLA alleles influencing risk of multiple sclerosis. Results are shown from fixed-effect meta-analysis across cohorts. Under a simple model (supplementary note), this factor can be estimated by comparing the difference in apparent heritability for major alleles between cases and controls. The dashed lines at 0 and 1 indicate, respectively, the case with no epistasis and the case where the standard deviation in the epistatically induced effect equals the average main effect. npg a n a ly s i s can be estimated using existing linear mixed-model methodology 28 , and simulations demonstrated that a study of this size is well powered to detect substantial epistasis if present (Supplementary Note).
We applied the approach independently to the key associated classical HLA alleles and combined the results across cohorts through metaanalysis (Fig. 3) . We found that, although the point estimate of the contribution of polygenic epistasis was substantial for some loci, the P value for a nonzero polygenic epistatic component was never less than 0.05, and, for the two most significant alleles (HLA-DRB1*15:01 and HLA-A*02:01), the point estimate was close to zero. Moreover, HLA-B*38:01, which showed the strongest effect, in being a rare allele might have greater population stratification than common alleles 29 , and a related estimator put the epistatic component for this allele at 0 (Supplementary Note). Overall, we conclude that there is no strong evidence for major polygenic epistasis modulating influence on classical HLA allele risk for multiple sclerosis.
Genetic influences on disease features
Finally, we considered whether HLA factors influence phenotypic features, including age at onset (n = 11,019), disease severity (MS severity score; n = 8,065) and clinical course (comparing primary progressive with relapsing onset disease; n = 12,450) (n is the number of cases for which data were available); Supplementary Table 5 ). First, we tested for association with an HLA-specific risk score obtained by multiplying the odds ratios of each individual's genotypes across loci. We found evidence for association between the HLA risk score and age at onset (P = 6.6 × 10 −10 ; Fig. 4a ), which was driven by the HLA-DQB*06:02-HLA-DRB1*15:01 haplotype (with each allele of HLA-DQB1*06:02 reducing age at onset by 0.72 years, P = 2 × 10 −8 ; comparable to previous estimates 9,30 ) (Fig. 4b) and the HLA-DQA*01:01-HLA-DRB1*01:01 haplotype (with each copy of HLA-DRB1*01:01 increasing age at onset by ~1.4 years, P = 2 × 10 −8 ) (Fig. 4c) . Data for other alleles on these haplotypes are shown in Supplementary Figure 7 . The preferred model for age at onset within the UK cohort included additive and independent effects for HLA-DQB1*06:02 and HLA-DRB1*01:01, although these alleles are in strong positive LD with HLA-DRB1*15:01 and HLA-DQA1*01:01, respectively (r = 0.97 and 0.76), and there was only a small difference in likelihood in comparison to a model involving these alleles (Supplementary Table 4 ). When the entire cohort was considered, the age-at-onset effect was better explained by a recessive effect for HLA-DQB1 alleles encoding a glycine at position 70 (Supplementary Table 4 ), again without evidence for an interaction. Consistent with earlier observations, we found no strong or consistent associations with other disease features 9 nor did we find evidence for interactions. In summary, genetic factors within the HLA region have only a weak effect on any aspect of disease subphenotype, and, where they do have an effect, it is in a manner broadly consistent with overall risk for multiple sclerosis, although without evidence for the interactions identified for disease risk.
DISCUSSION
Our results establish important features of the architecture of genetic risk for multiple sclerosis. In particular, a picture of relative simplicity emerges, with a series of class II risk alleles (consistent with most being driven by HLA-DRB1) alongside a series of protective class I alleles and with no strong contribution to disease severity or clinical course. Such findings are in direct contrast to the complexity found in inflammatory bowel diseases (IBD) 31 . Rather, we find a landscape largely absent of statistical interactions involving classical HLA alleles at the loci studied, although there are occasional substantial modulating effects for particular allelic combinations. These findings raise questions about disease mechanisms that require analysis in functional studies. For example, the finding that the protective effect of the HLA-DQA1*01:01-bearing haplotype is restricted to HLA-DRB1*15:01 carriers suggests the possibility of a process mediated by T cell receptor cross-reactivity (as proposed for HLA-DRB1*15:01-HLA-DRB5 interactions 32 ). In contrast, the lack of interactions between class I and class II alleles suggests that the respective risk and protective effects of alleles within these two systems may act through very different mechanisms. The presence of multiple protective alleles, including rare alleles with strong effects (HLA-B*38:01, frequency ~1.1% in UK controls; HLA-B*55:01, frequency ~1.8% in UK controls), raises the question of whether carriers of these different alleles share related immunological properties that can potentially be manipulated through therapeutic intervention. More generally, although more might be learned from the use of even larger sample sizes, our finding of a modest contribution of interactions to variation in genetic risk suggests that epistasis involving classical HLA alleles does not contribute substantially to missing heritability 33 in multiple sclerosis.
URLs. British 1958 Birth Cohort, http://www.b58cgene.sgul.ac.uk/; IMGT, http://www.ebi.ac.uk/ipd/imgt/hla/align.html.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. SNP genotypes are available upon request from the International Multiple Sclerosis Genetics Consortium via Jonathan Haines (jonathan.haines@case.edu). npg a n a ly s i s frequency after imputation across cohorts of 0.5%. This step removed 55 alleles of 232 across the loci considered. (iii) We removed alleles imputed to be in perfect association (r 2 = 1) with each other. This step removed 8 of 177 alleles.
(iv) We removed individuals for whom the imputed allele was not present in the IMGT database. This step removed 530 of 47,849 individuals.
Starting with a baseline model including effects for each cohort (as a factor) and principal components, at each stage, we performed logistic regression on disease risk for every classical HLA allele in turn, considering a general genotype model (separate coefficients for each genotype). Consequently, the allele that led to the highest increase in likelihood was identified, and, in a separate step, the Bayesian information criterion (BIC) was used to decide whether the effect was best described as additive, recessive, dominant or general. A range of strategies for backward elimination were considered, although in practice no allele was ever removed. The model selection process was run until the BIC no longer increased. However, only effects that also achieved P < 1 × 10 −9 in the fixed-effect meta-analysis are reported. A summary of the factors identified at each step and how these relate to the factors identified by the other approaches is shown in Supplementary Figure 2 .
We note that we also considered an automated search including SNP variants. However, because most classical HLA alleles are well tagged by at least one (and often many) SNP within the region, we commonly observed that effects that are typically interpreted as being driven by classical HLA alleles were assigned to SNPs (potentially owing to errors in imputation and/or chance fluctuations in association). We therefore only considered classical HLA alleles in the automated approach, although we compared results to the manually curated selection process to check consistency.
Approach 3: automated model search augmented with allele groupings at the two-digit level and by sharing of amino acids at variable residues. Previous research has demonstrated that some association between groups of classical HLA alleles and genetic risk for disease can be explained by the sharing of particular amino acid residues at variable sites within the mature protein 14 . We therefore considered a separate automated model search strategy on the combined cohorts in which we augmented the set of HLA alleles by genotypes at allele groups defined by both two-digit resolution and the sharing of specific amino acid residues at variable sites. Group membership was inferred from the imputed allele at four-digit resolution. Aligned amino acid sequences for the imputed alleles were obtained from IMGT on 4 March 2015. In a few instances, full amino acid sequences were not available for all alleles imputed.
We took the following steps: (i) we set the threshold for imputation to be 0, that is, taking the allele call with the highest posterior probability in each case and treating it as fixed. (ii) We removed alleles or allele groups with a combined frequency after imputation across cohorts of 0.5%. This step removed 108 alleles and allele groups of 454 across the loci considered. (iii) We removed alleles or allele groups imputed to be in perfect association (r 2 = 1) with each other. This step removed 22 of 346 alleles and allele groups. (iv) We removed individuals for whom the imputed allele was not present in the IMGT database. This step removed 530 of 47,849 individuals.
We considered a general genotype model for each allele or allele group at each step, starting from a baseline model with coefficients for each cohort and principal components. At each stage, the allele or allele group leading to the greatest increase in likelihood was identified, and BIC was used to assign additive, dominant, recessive or general models. The procedure was run until BIC no longer increased, although only effects that achieved P < 1 × 10 −9 in the fixed-effect meta-analysis are reported. A summary of the effects identified at each stage is shown in Supplementary Figure 2. Consensus strategy and comparison. The three model selection strategies identified a series of related although non-identical effects ( Supplementary  Fig. 2) . Moreover, in two cases, the effects identified by the automated approaches were better described as interactions. For example, the homozygous protective effect identified as associated with HLA-DQB1 alleles with a glycine at residue 70 in step (vii) of the augmented model selection process was better explained (the data were 400 times more likely) through an interaction with HLA-DRB1*15:01.
Integrating uncertainty in classical allele imputations. To ensure that the identified associations were not affected by imputation quality, additional analyses where conducted where the uncertainty associated with imputation (quantified by the posterior probability of each call) was incorporated into the logistic regression framework, with numerical optimization used to find maximum-likelihood estimates. Specifically, for every classical allele, we fitted logistic models with additive and non-additive effects for HLA-DRB1*15:01 and HLA-A*02:01, the top five principal components and the allele in question (with the disease model inferred from the initial analysis), with no uncertainty (alleles treated as perfectly measured) and with uncertainty (integrating out uncertainty in the genotype). Correspondence in the effect sizes and statistical significance are shown in Supplementary Figure 1. Secondary phenotypes. Secondary phenotypes, including clinical course (primary progressive versus relapsing remitting multiple sclerosis), severity (calculated by the multiple sclerosis severity score, MSSS, which reflects the rate at which patients affected with the disease accumulate disability 36 ) and age at onset were available for a proportion of the samples studied (Supplementary Table 5 ). We used a combination of manually curated and automated searches to explore genetic associations to secondary phenotypes. Details are provided in the Supplementary Note.
Interactions among classical HLA alleles. To investigate potential interactions between the HLA alleles included in our model and other HLA alleles, we first ran models with (i) two parameters (one additive and one homozygote correction term) to model the effects of HLA-DRB1*15:01 and HLA-A*02:01; (ii) parameters for each of the top five principal components; (iii) a single parameter included for each other SNP or HLA allele identified as associated with multiple sclerosis in this analysis (additive on the log-odds scale for all alleles apart from HLA-DRB1*03:01 and HLA-DQB1*03:02, where a recessive and a dominant effect, respectively, were assumed); (iv) a single parameter (additive on the log-odds scale) for each other HLA allele in turn; and (v) an interaction term, which models the effect of each other HLA allele in the presence of the allele under consideration. Quantile-quantile plots of the interaction term for these analyses are shown in Figure 2 and Supplementary  Figure 3 for the UK cohort.
Interactions between classical HLA alleles and non-HLA associated loci. We assessed evidence of interaction between HLA risk alleles and non-HLA risk loci associated with multiple sclerosis identified in the recent Immunochip study 11 , by fitting models with (i) risk parameters for the classical HLA allele as identified above ( Table 1) ; (ii) parameters for the top five principal components; (iii) a parameter for the non-HLA variant (additive on the log-odds scale); and (iv) an interaction parameter for the effect of the non-HLA SNP in the presence of the classical HLA allele in question. Quantile-quantile plots of the interaction term for these analyses are shown in Figure 2 and Supplementary Figure 4 for the UK cohort.
For HLA-A*02:01, initial evidence for deviation from the expected uniform distribution of P values led to the identification of a weak non-additive effect of the allele, correction for which removed any evidence for HLA-non-HLA interactions (Supplementary Fig. 6 ).
We also asked whether the effect of HLA alleles on multiple sclerosis risk was stratified by the cumulative risk from the non-HLA effects. To do this, we divided the samples (combined cases and controls within the UK cohort) into quartiles of non-HLA risk score (RS), defined by combining information across the L loci found associated in ref. npg Estimating the contribution of polygenic epistasis to HLA allele risk. To assess whether many weak effects spread across the genome modulate the genetic risk for multiple sclerosis arising from classical HLA alleles, we developed and validated a new statistical approach that exploits the idea that interactions generate case-only LD among interacting alleles. Full details of the method are provided in the Supplementary Note.
